Sun Pharma Reports Two-Year LEQSELVI Data In Severe Alopecia Areata
(RTTNews) - Thursday, Sun Pharmaceutical Industries Limited (SUNPHARMA) reported two-year safety and efficacy data for LEQSELVI (deuruxolitinib) in adults with severe alopecia areata at the 2026 European Academy of Dermatology and Venereology (EADV) Congress.
The data from a European open-label extension study showed that the safety profile of LEQSELVI remained generally consistent with previous clinical experience through two years of treatment. Most treatment-emergent adverse events were mild or moderate, while treatment discontinuations due to adverse events were uncommon.
Severe Alopecia Areata & LEQSELVI
Alopecia areata is a chronic autoimmune disease in which the immune system attacks hair follicles, resulting in hair loss on the scalp and other parts of the body. Severe forms of the disease can result in extensive scalp hair loss.
LEQSELVI (deuruxolitinib) is an FDA-approved oral selective JAK1 and JAK2 inhibitor for adults with severe alopecia areata. The 8 mg twice-daily dose was evaluated in the long-term safety analysis.
Long-Term Efficacy
Long-term analyses showed sustained scalp hair regrowth through Week 108. Among open-label extension baseline responders with a SALT score of =20 who maintained response at Week 52, 93.9% maintained their response at Week 108.
Among baseline nonresponders with a SALT score above 20, 76.6% achieved a response by Week 52. Of those who continued treatment after responding, 96.8% maintained their response through Week 108.
Safety Data
The two-year safety analysis showed that most treatment-emergent adverse events were mild or moderate. No deaths, thrombosis or major adverse cardiovascular events were reported among patients receiving the FDA-approved 8 mg twice-daily dose.
Sun Pharma also reported that discontinuations due to adverse events were uncommon, supporting the long-term safety evaluation of LEQSELVI in severe alopecia areata.
Additional Data
Sun Pharma presented seven LEQSELVI presentations at EADV 2026, including pooled analyses from the THRIVE-AA1 and THRIVE-AA2 studies.
The analyses showed consistent efficacy across patient subgroups, including those with eyebrow, eyelash or nail involvement and patients with shorter- or longer-duration disease episodes.
Sun Pharma's stock closed trading at INR 1,801.00, down 0.86 percent on the National Stock Exchange.
